Oruka Therapeutics Reports Positive Early-Stage Data for ORKA-001, Advocating for Longer Dosing Intervals and Announcing $180 Million Private Placement Plans
Interim Trial Results: Oruka Therapeutics (ORKA) announced positive interim data from an early-stage trial of its long-acting treatment.
Significance of Findings: The results suggest potential effectiveness and safety, paving the way for further development in clinical trials.
Trade with 70% Backtested Accuracy
Analyst Views on ORKA
About ORKA
About the author
Five Below Options Volume Hits 7,969 Contracts, 71.5% of Daily Average
- Active Options Trading: Five Below Inc's options volume reached 7,969 contracts today, equivalent to approximately 796,900 shares, indicating significant market activity and representing 71.5% of its average daily trading volume of 1.1 million shares over the past month.
- High Demand Options: Notably, the $220 strike call option expiring on January 16, 2026, saw 1,886 contracts traded today, representing about 188,600 shares, reflecting strong market interest at this price level.
- PureCycle Trading Activity: Concurrently, PureCycle Technologies Inc experienced options trading volume of 27,453 contracts, equivalent to approximately 2.7 million shares, which is about 71.3% of its average daily trading volume of 3.9 million shares over the past month, indicating investor attention on this stock as well.
- Put Option Activity: Within PureCycle, the $11 strike put option expiring on March 20, 2026, saw 3,979 contracts traded today, representing approximately 397,900 shares, reflecting a cautious market sentiment regarding the stock's future performance.
Oruka to Present Novel Biologics at 44th Annual J.P. Morgan Healthcare Conference
- Conference Presentation: Oruka Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the biologics sector.
- Innovative Treatment: Oruka is developing novel biologics targeting chronic skin diseases like plaque psoriasis, aiming for high rates of complete disease clearance with dosing as infrequently as once or twice a year, significantly improving patients' quality of life.
- Technological Advantage: The biologics are engineered by Paragon Therapeutics to target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases, showcasing the company's R&D strength and market potential in biotechnology.
- Investor Relations: Oruka will provide a webcast and replay of the presentation on its investor events website, enhancing engagement with investors and increasing transparency to attract more attention to its innovative products.
Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming
- ETF Performance Decline: The Sprott Silver Miners & Physical Silver ETF fell approximately 2.3% in Wednesday afternoon trading, reflecting a weak sentiment towards silver mining stocks that could impact investor confidence.
- Individual Stock Weakness: Shares of Americas Gold and Silver dropped about 2.8%, while Vizsla Silver declined by approximately 1.6%, indicating the vulnerability of these companies in the current market environment, potentially leading to capital outflows.
- Market Trend Analysis: The overall decline of the ETF is linked to fluctuations in silver prices and investor risk aversion towards mining stocks, which may influence future investment decisions and capital allocation.
- Investor Focus: As silver mining stocks continue to struggle, investors may need to reassess their allocations within precious metal portfolios to mitigate potential market risks.
Gilead Sciences Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Thursday
Analyst Coverage Initiations: BMO Capital initiated coverage on Veeva Systems with a Market Perform rating and a price target of $300, while Scotiabank rated Gilead Sciences as Sector Outperform with a target of $140.
Buy Ratings Issued: Roth Capital initiated coverage on CPS Technologies with a Buy rating and a price target of $6, and Jefferies rated Oruka Therapeutics with a Buy and a target of $45.
CoreWeave Rating: Compass Point initiated coverage on CoreWeave with a Buy rating and a price target of $150, reflecting positive sentiment towards the stock.
Current Stock Prices: As of Wednesday, Veeva closed at $296.96, Gilead at $123.40, CPS Technologies at $3.30, Oruka Therapeutics at $28.30, and CoreWeave at $85.43.
AutoZone Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Thursday
Analyst Upgrades: Goldman Sachs upgraded AutoZone Inc. from Neutral to Buy, raising its price target from $4,090 to $4,262, while also increasing On Holding AG's target from $50 to $52, maintaining a Neutral rating.
Analyst Downgrades: Deutsche Bank cut Circle Internet Group Inc.'s price target from $147 to $90, maintaining a Hold rating, and Goldman Sachs downgraded Dollar Tree Inc. from Buy to Sell, lowering its target from $133 to $103.
Price Target Adjustments: Morgan Stanley raised Cisco Systems Inc.'s price target from $77 to $82, while B of A Securities increased FedEx Corp.'s target from $270 to $285, both maintaining their respective ratings.
Mixed Ratings: BTIG cut Flutter Entertainment PLC's price target from $321 to $271 but maintained a Buy rating, while HC Wainwright & Co. reduced Largo Inc.'s target from $3.7 to $2.9, also keeping a Buy rating.
BTIG Reaffirms Buy Rating for Oruka Therapeutics and Increases Price Target to $63
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Users can access the most accurate stock market intelligence to improve their trading outcomes.
Five Below Options Volume Hits 7,969 Contracts, 71.5% of Daily Average
- Active Options Trading: Five Below Inc's options volume reached 7,969 contracts today, equivalent to approximately 796,900 shares, indicating significant market activity and representing 71.5% of its average daily trading volume of 1.1 million shares over the past month.
- High Demand Options: Notably, the $220 strike call option expiring on January 16, 2026, saw 1,886 contracts traded today, representing about 188,600 shares, reflecting strong market interest at this price level.
- PureCycle Trading Activity: Concurrently, PureCycle Technologies Inc experienced options trading volume of 27,453 contracts, equivalent to approximately 2.7 million shares, which is about 71.3% of its average daily trading volume of 3.9 million shares over the past month, indicating investor attention on this stock as well.
- Put Option Activity: Within PureCycle, the $11 strike put option expiring on March 20, 2026, saw 3,979 contracts traded today, representing approximately 397,900 shares, reflecting a cautious market sentiment regarding the stock's future performance.
Oruka to Present Novel Biologics at 44th Annual J.P. Morgan Healthcare Conference
- Conference Presentation: Oruka Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the biologics sector.
- Innovative Treatment: Oruka is developing novel biologics targeting chronic skin diseases like plaque psoriasis, aiming for high rates of complete disease clearance with dosing as infrequently as once or twice a year, significantly improving patients' quality of life.
- Technological Advantage: The biologics are engineered by Paragon Therapeutics to target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases, showcasing the company's R&D strength and market potential in biotechnology.
- Investor Relations: Oruka will provide a webcast and replay of the presentation on its investor events website, enhancing engagement with investors and increasing transparency to attract more attention to its innovative products.
Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming
- ETF Performance Decline: The Sprott Silver Miners & Physical Silver ETF fell approximately 2.3% in Wednesday afternoon trading, reflecting a weak sentiment towards silver mining stocks that could impact investor confidence.
- Individual Stock Weakness: Shares of Americas Gold and Silver dropped about 2.8%, while Vizsla Silver declined by approximately 1.6%, indicating the vulnerability of these companies in the current market environment, potentially leading to capital outflows.
- Market Trend Analysis: The overall decline of the ETF is linked to fluctuations in silver prices and investor risk aversion towards mining stocks, which may influence future investment decisions and capital allocation.
- Investor Focus: As silver mining stocks continue to struggle, investors may need to reassess their allocations within precious metal portfolios to mitigate potential market risks.
Gilead Sciences Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Thursday
Analyst Coverage Initiations: BMO Capital initiated coverage on Veeva Systems with a Market Perform rating and a price target of $300, while Scotiabank rated Gilead Sciences as Sector Outperform with a target of $140.
Buy Ratings Issued: Roth Capital initiated coverage on CPS Technologies with a Buy rating and a price target of $6, and Jefferies rated Oruka Therapeutics with a Buy and a target of $45.
CoreWeave Rating: Compass Point initiated coverage on CoreWeave with a Buy rating and a price target of $150, reflecting positive sentiment towards the stock.
Current Stock Prices: As of Wednesday, Veeva closed at $296.96, Gilead at $123.40, CPS Technologies at $3.30, Oruka Therapeutics at $28.30, and CoreWeave at $85.43.
AutoZone Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Thursday
Analyst Upgrades: Goldman Sachs upgraded AutoZone Inc. from Neutral to Buy, raising its price target from $4,090 to $4,262, while also increasing On Holding AG's target from $50 to $52, maintaining a Neutral rating.
Analyst Downgrades: Deutsche Bank cut Circle Internet Group Inc.'s price target from $147 to $90, maintaining a Hold rating, and Goldman Sachs downgraded Dollar Tree Inc. from Buy to Sell, lowering its target from $133 to $103.
Price Target Adjustments: Morgan Stanley raised Cisco Systems Inc.'s price target from $77 to $82, while B of A Securities increased FedEx Corp.'s target from $270 to $285, both maintaining their respective ratings.
Mixed Ratings: BTIG cut Flutter Entertainment PLC's price target from $321 to $271 but maintained a Buy rating, while HC Wainwright & Co. reduced Largo Inc.'s target from $3.7 to $2.9, also keeping a Buy rating.
BTIG Reaffirms Buy Rating for Oruka Therapeutics and Increases Price Target to $63
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Users can access the most accurate stock market intelligence to improve their trading outcomes.
